MARKETS / NYSE / STXS
NYSE · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Stereotaxis, Inc. STXS

17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$32.4M
▲ 20.3% vs FY2024
EPS · FY25
$-0.25
Dividend / sh · FY25
Payout · FY25
-0%
ROE · FY25
-221.3%
Net margin · FY25
-66.8%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 32.4M
Revenue, FY2025 · full 17-year series below
Revenue Net income
0.020.040.060.0-0.02009201220152018202120242025
0.020.040.060.0-0.02016201920222025

The company lost 67 cents on every revenue dollar this year.

Per share
USD -0.25
Diluted EPS, FY2025
EPS
0.40.81.2-0.252009201220152018202120242025
0.40.81.2-0.252016201920222025

The company pays no cash dividend.

Profitability
-221.3%
Return on equity, FY2025
ROE
0.250.50.751-221.3%2009201220152018202120242025
0.250.50.751-221.3%2016201920222025
Operating margin-68.3%
Net margin-66.8%
Return on assets-43.7%

Each USD of equity lost 221 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit-0.0%
Consecutive raises

Growth
+4.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+4.8%
+4.0%
−1.5%
−3.4%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
Shares outstanding, FY2025
0.010.002009201220152018202120242025
0.000.002016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 52.3M
total assets, end of FY2025
Total assetsUSD 52.3M
EquityUSD 13.5M
CashUSD 13.4M
Current ratio1.51×

Equity funds 26% of total assets.

History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.1
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.25
−0.30
−0.27
−0.26
−0.16
−0.11
−0.10
−0.03
−0.32
−0.54
−0.35
−0.26
−5.95
−1.33
−5.84
−3.94
−0.63
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
−0
−0
−0
−0
−0
−0
·
·
−0
−0
−0
−0
−0
·
·
·
·
ROE %
−221.3
−214.5
−97.0
−60.8
−31.3
−23.2
−38.1
·
·
·
·
·
·
·
·
−219.9
−359.8
Shares out B
·
·
·
·
·
·
·
·
·
0.00
·
·
·
0.01
0.01
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
65 of 65
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed